Live herpes simplex virus (HSV) vaccines:
The only treatment option with the potential to eradicate all forms of herpetic disease.
Through faithfully re-creating every facet of the HSV life cycle, live HSV vaccines prepare the human immune system to do battle with the natural pathogen. The viability of the approach has been established with the VZV Oka vaccine, a live-attenuated variant of a similar alpha-herpesvirus, which shares 60 genes in common with HSV-1 and HSV-2. The Oka vaccine has profoundly curbed the incidence of chickenpox over the past 20 years. An equivalent outcome may be accomplished with rationally-engineered live HSV vaccines, which retain more than 99% of the antigenic breadth of their naturally occurring HSV counterparts.
The approach has been established with the VZV Oka vaccine, a live-attenuated variant of a similar alpha-herpesvirus…which has profoundly curbed the incidence of chickenpox over the past 20 years.
Numerous HSV-2 subunit vaccine candidates have been proposed to slow the spread of HSV-2. The 99% of HSV-2 proteins that are missing from subunit vaccines prevents them from adequately preparing the immune system to fight a formidable adversary. HSV-2 is at least 100 times more complex than any subunit vaccine tested to date. HSV-2 subunit vaccines have been failing to offer any real protection against HSV-2 in clinical trials dating back 30 years. Learn more about why RVx’s HSV vaccines are superior.